Pay oncologists for the time it takes to enrol a patient
Discussing and enrolling a patient in a trial takes an oncologist far longer than prescribing the usual treatment, and they are not paid for it. Paying for that time would remove a quiet disincentive.
Health systems and payers create a reimbursable code or protected-time allocation for trial discussion and enrolment (analogous to advance-care-planning codes), and sponsors' per-patient budgets include physician time explicitly rather than folding it into overhead. Academic promotion criteria count enrolment.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
Pages like this
not linked directly; found by shared links- IdeaRemote consent and tele-screening so the first trial visit is a video call
Shares Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes, Trials enrol too few, too slowly.
- IdeaEvery payer covers routine care costs for trial participants, in every country
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.
- IdeaLay trial navigators funded per centre, evaluated in a randomised trial
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.
- IdeaStop excluding people with a prior cancer, controlled HIV, or treated hepatitis
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.
- IdeaA public equity index for trial sites and sponsors, tied to funding
Shares American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains.
- IdeaCap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales
Shares American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains.
- IdeaSet trial enrolment targets from who actually gets the disease, and publish progress live
Shares Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes, Trials enrol too few, too slowly.
- IdeaJust-in-time site activation: open a site in two weeks when a patient appears
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.